SLU-PP-332 is an investigational peptide-based metabolic modulator developed in academic research settings (not a commercial pharmaceutical). It is primarily studied for its ability to activate estrogen-related receptors (ERRs)—a group of nuclear receptors involved in energy balance, mitochondrial function, and fat metabolism.
What It Does (Proposed Mechanism)
SLU-PP-332 is believed to:
- Activate ERRα and ERRγ, which regulate genes involved in:
- Mitochondrial biogenesis
- Fatty acid oxidation
- ATP production
- Increase the body’s shift toward burning fatty acids for fuel
- Improve cellular energy efficiency
- Mimic some metabolic benefits similar to endurance exercise at a molecular level (“exercise mimetic” properties—still theoretical)
Potential Benefits (Research-Based Only)
Current findings are from preclinical studies (animal/lab):
- Improved metabolism & energy expenditure
- Enhanced mitochondrial output
- Reduced fat accumulation
- Possible support for glucose regulation
- Proposed benefits for fatigue, endurance, and metabolic health
